Journal
FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.702360
Keywords
small-molecule inhibitors; epigenetic drugs; epigenetic reprogramming; cancer biomarker; histone modification; microRNA
Categories
Funding
- Natural Science Foundation of China [81402507, 81900339, 82073311]
- Health Commission of Sichuan Province [19ZDXM0016]
- Science amp
- Technology Department of Sichuan Province [2018SZ0033, 2018JY0542]
- Key Research and Development Projects in Chengdu [2020-YF05-00058-SN]
- Key Research and Development Projects in Sichuan Province [2020YFS0399]
- Fundamental Research Funds for the Central Universities [2682021TPY031]
Ask authors/readers for more resources
Cancer treatment remains a significant challenge globally, with epigenetic modification being identified as a key target for drug development. By adding chemical groups to the DNA backbone and modifying chromatin architecture through various enzymes, epigenetic drugs have shown promising effects in both preclinical and clinical studies. Developing small-molecule inhibitors targeting epigenetic modified enzymes has become a focus for future cancer therapy research.
Cancer treatment is a significant challenge for the global health system, although various pharmacological and therapeutic discoveries have been made. It has been widely established that cancer is associated with epigenetic modification, which is reversible and becomes an attractive target for drug development. Adding chemical groups to the DNA backbone and modifying impart distinct characteristics on chromatin architecture. This process is mediated by various enzymes modifying chromatin structures to achieve the diversity of epigenetic space and the intricacy in gene expression files. After decades of effort, epigenetic modification has represented the hallmarks of different cancer types, and the enzymes involved in this process have provided novel targets for . Epigenetic drugs show significant effects on both preclinical and clinical studies in which the target development and research offer a promising direction for cancer therapy. Here, we summarize the different types of epigenetic enzymes which target corresponding protein domains, emphasize DNA , histone modifications, and microRNA-mediated cooperation with epigenetic modification, and highlight recent achievements in developing targets for epigenetic inhibitor therapy. This article reviews current anticancer small-molecule inhibitors targeting epigenetic modified enzymes and displays their performances in different stages of clinical trials. Future studies are further needed to address their off-target effects and cytotoxicity to improve their clinical translation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available